DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Lip GYH, Pan X, Kamble S. , et al.
Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: apixaban, warfarin, dabigatran, or rivaroxaban.
PLoS One 2018;
13 (04) e0195950
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.